Cholangiocarcinoma PDX Models

Identifying robust preclinical models for cholangiocarcinoma is essential for the development of targeted therapies. Patient-derived xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity. The CrownBio cholangiocarcinoma PDX collection consists of several models which provide an accurate approach to predicting an agents efficacy prior to entering the clinic. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
CC0449CholangiocarcinomaECCVIEW MODEL
CC11307CholangiocarcinomaADCVIEW MODEL
CC1470CholangiocarcinomaICCVIEW MODEL
CC6204CholangiocarcinomaICCVIEW MODEL
CC6205CholangiocarcinomaICCVIEW MODEL
CC6216CholangiocarcinomaNAVIEW MODEL
CC6279CholangiocarcinomaICCVIEW MODEL
CC6600CholangiocarcinomaICCVIEW MODEL
CC6604CholangiocarcinomaICCVIEW MODEL
CC6607CholangiocarcinomaICCVIEW MODEL